Insys Therapeutics, Inc. to Present at Two Upcoming Conferences in June

PHOENIX, May 26, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. ("Insys" or "the Company") INSY today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at two upcoming conferences in June as follows:

The presentations will be webcast live at the aforementioned times as well as archived for 90 days thereafter, via the Company's website at www.insysrx.com, under the Investors Section.

About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product: Subsys^® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Subsys^® and Syndros™ are registered trademarks of Insys Therapeutics, Inc.